Cyclin-Dependent Kinase 5 Controls TRPV1 Membrane Trafficking and the Heat Sensitivity of Nociceptors through KIF13B

Bao-Ming Xing,1* Yan-Rui Yang,1* Jun-Xia Du,1* Hai-Jing Chen,1 Cai Qi,1 Zhi-Hua Huang,1 Ying Zhang,1 and Yun Wang1

1Neuroscience Research Institute and Department of Neurobiology, The Key Laboratory for Neuroscience of the Ministry of Education and Health, Peking University Health Science Center, Beijing 100191, China, 2State Key Laboratory of Molecular and Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China, and 3Gannan Medical College, Ganzhou, Jiangxi, 341000, China

The number of functional transient receptor potential vanilloid 1 (TRPV1) channels at the surface, especially at the peripheral terminals of primary sensory neurons, regulates heat sensitivity, and increased surface localization of TRPV1s contributes to heat hyperalgesia. However, the mechanisms for regulating TRPV1 surface localization are essentially unknown. Here, we show that cyclin-dependent kinase 5 (Cdk5), a new player in thermal pain sensation, positively regulates TRPV1 surface localization. Active Cdk5 was found to promote TRPV1 anterograde transport in vivo, suggesting a regulatory role of Cdk5 in TRPV1 membrane trafficking. TRPV1-containing vesicles bind to the forkhead-associated ( FHA) domain of the KIF13B (kinin-3 family member 13B) and are thus delivered to the cell surface. Overexpression of Cdk5 or its activator p35 promoted and inhibition of Cdk5 activity prevented the KIF13B–TRPV1 association, indicating that Cdk5 promotes TRPV1 anterograde transport by mediating the motor–cargo association. Cdk5 phosphorylates KIF13B at Thr-506, a residue located in the FHA domain. T506A mutation reduced the motor–cargo interaction and the cell-permeable TAT–T506 peptide, targeting to the Thr-506, decreased TRPV1 surface localization, demonstrating the essential role of Thr-506 phosphorylation in TRPV1 transport. Moreover, complete Freund’s adjuvant (CFA) injection-induced activation of Cdk5 increased the anterograde transport of TRPV1s, contributing to the development and possibly the maintenance of heat hyperalgesia, whereas intrathecal delivery of the TAT–T506 peptide alleviated CFA-induced heat hyperalgesia in rats. Thus, Cdk5 regulation of TRPV1 membrane trafficking is a fundamental mechanism controlling the heat sensitivity of nociceptors, and moderate inhibition of Thr-506 phosphorylation during inflammation might be helpful for the treatment of inflammatory thermal pain.

Introduction

Transient receptor potential vanilloid 1 (TRPV1), a calcium-permeable nonselective cation channel highly expressed in primary sensory neurons, is an important detector of noxious heat (>43°C) under normal conditions (Caterina et al., 1997, 2000) and is suggested as a central mediator of inflammatory heat hyperalgesia because multiple proinflammatory mediators, such as bradykinin, prostaglandin E2, NGF, and ATP, can potentiate its channel function (Szallasi et al., 2007).

As a transmembrane receptor, the number of functional TRPV1s at the plasma membrane must be a critical determinant of channel function, and potentiating channel function by increasing its levels at the cell surface is a potential mechanism underlying proinflammatory mediator-induced heat hyperalgesia (Ji et al., 2002; Van Buren et al., 2005; Zhang et al., 2005; Stein et al., 2006; Camprubi-Robles et al., 2009). In general, the number of receptors at the surface can be regulated by the membrane trafficking and insertion of receptors. To date, studies have shown that PKC activation-sensitized SNARE-dependent exocytosis and Src-dependent phosphorylation of TRPV1 are involved in inflammatory stimuli-induced rapid membrane insertion of TRPV1s from a ready-to-go vesicular pool (Morenilla-Palao et al., 2004; Zhang et al., 2005; Camprubi-Robles et al., 2009), but the mechanisms that regulate transport of TRPV1s from the Golgi apparatus to the plasma membrane of sensory neurons is essentially unclear. Kinesin superfamily motor proteins are responsible for the intracellular anterograde transport of most cargos, including transmembrane receptors (Hirokawa et al., 2009). However, the kinesin motor that anterogradely transports TRPV1-containing vesicles is also unclear.

Protein kinases play a pivotal role in modulating TRPV1 channel function (Huang et al., 2006). Recently, our group, along
with Pareek’s group, revealed that cyclin-dependent kinase 5 (Cdk5) in primary sensory neurons regulates heat sensitivity. Cdk5 activity is required for the basal response to noxious heat (Pareek et al., 2006, 2007), and activation of Cdk5 is involved in inflammatory heat hyperalgesia (Yang et al., 2007). In cultured DRG neurons, inhibition of Cdk5 results in a significant decrease in capsaicin-evoked calcium influx (Pareek et al., 2007), suggesting that Cdk5 might modulate TRPV1.

Cdk5 is involved in many cellular processes of the nervous system, including vesicle transport. Sustained Cdk5 activity is required for normal kinesin-driven motility in neurons (Ratner et al., 1998) and vesicle transport from the Golgi to neurites (Pagli et al., 2001). In the present study, we investigated whether and how Cdk5 regulates TRPV1 membrane trafficking. Through bioinformatics analysis, we find one potential phosphorylation site for Cdk5 at Thr–506 located in the forhead-associated (FHA) domain of the kinesin-3 family motor protein GAKIN (guanylate kinase-associated kinesin)/KIF13B (kinesin-3 family member 13B). We demonstrate that KIF13B can indeed transport TRPV1s and Cdk5 promotes the trafficking process by mediating the motor–cargo association, which is at least partially dependent on Cdk5-mediated phosphorylation of KIF13B at Thr–506. We further investigated whether this regulatory mechanism contributes to inflammatory heat hyperalgesia. In vivo studies indicate that inflammation induces activation of Cdk5 which, in turn, increases TRPV1 trafficking to the periphery, whereas inhibition of Thr–506 phosphorylation during inflammation alleviates heat hyperalgesia.

Materials and Methods

Plasmids, antibodies, and chemicals. The plasmids pcDNA3.1(+)/Cdk5, pcDNA3.1(+)/D144N–Cdk5, and pEGFP–C2–p35 were constructed as described previously (Wang et al., 2006; Yang et al., 2007). cDNA fragments encoding the corresponding domains of KIF13B were generated by PCR amplification from a rat brain cDNA pool and subcloned into pEGFP–C2 (Clontech) or pET–28a(+) (Novagen). Mutations (T506A, T506D) within the FHA domain were created with the TAT fusion peptides were synthesized by GL Biochem. Vinculin and pTet off regulatory system (TRPV1–CHO cells) were cultured in Ham’s F-12 medium containing 10% FBS, 0.25 mg/ml geneticin, and 100 ng/ml mouse NGF (Promega). Five micromolar AraC (Sigma–Aldrich) was added to the culture 18–24 h after plating and maintained until the end of experiments. The cultures were infected with lentiviruses (LVs) on day 3 or treated with the TAT fusion peptides (10 µM) or roscovitine (30 µM) on day 7.

RNA interference. RNA interference (RNAi) LVs coexpressing EGFP and shRNAs against rat KIF13B were purchased from Shanghai GeneChem. The target mRNA sequence was as follows: 5′-GGCCAUAUGAAGUUGGAUAACUAAA-3′ (Yoshimura et al., 2010). LVs expressing shRNAs targeting a nonspecific sequence were used as controls. To downregulate KIF13B expression in cultured DRG neurons, 1 × 10⁵ lentiviral particles were added to one 35 mm dish (multiplicity of infection of ~50), and the neurons were cultured for 4–5 d.

Western blot. Tissues were homogenized in ice-cold lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1.5 mM MgCl₂, 10% glycerol, 1% Triton X-100, 5 mM EGTA, 0.5 µg/ml leupeptin, 1 mM PMSF, 1 mM NaVO₃, 10 mM NaF, and proteasine inhibitor mixture) and rotated at 4°C for 1 h before the supernatant was extracted. LV-infected DRG neurons were lysed in lysis buffer, and the supernatant was extracted by centrifugation at 12,000 × g at 4°C for 5 min. Equal amounts of protein extracts were denatured and subjected to SDS-PAGE. After separation, proteins were transferred to nitrocellulose membranes (Bio-Rad). The membranes were blocked with 5% nonfat milk in TBST (25 mM Tris, pH 7.4, 137 mM NaCl, 2.7 mM KCl, and 0.05% Tween 20) for 1 h at room temperature and incubated with an anti-TRPV1 antibody (1:200 dilution) or anti-KIF13B antibody (1:500 dilution) overnight at 4°C. After washing three times with TBST, the membranes were incubated with secondary antibody (1:2000 dilution) overnight at 4°C, then washed again, and finally developed with ECL solutions (Santa Cruz Biotechnology).

Immunoprecipitation. For coinmunoprecipitation (Co-IP), protein extracts from transfected cells were prepared as described above. Extract containing 400–500 µg of protein was incubated at 4°C for 3 h with 2 µg of anti-TRPV1, anti-phospho-Thr, anti-Cdk5, or anti-p35 antibody before incubation with protein A-Sepharose CL-4B resin (GE Healthcare) overnight. Immunoprecipitates were washed five times with TBS containing 0.1% Triton X-100 and then immunoblotted with an anti-GFP antibody. For immunoprecipitation, protein extracts from rat sciatic nerves and different parts of rat DRG were incubated with an anti-TRPV1 antibody, and the precipitated proteins were immunoblotted with an anti-TRPV1 antibody.

Pull-down assay. His₅ fusion proteins were expressed in Escherichia coli BL21 (DE3) cells and purified using nickel–nitrilotriacetic acid agarose beads (Novagen) according to the instructions of the manufacturer. The monoclonal anti-β-actin (TA-09), anti-N-cadherin (ZM-0094), and anti-His (TA-02) antibodies were purchased from Zymed, Santa Cruz Biotechnology, and Novagen, respectively. Pull-down samples were subjected to SDS-PAGE, transferred to nitrocellulose membranes (Bio-Rad), and immunoblotted with an anti-β-actin antibody (1:5000 dilution) overnight at 4°C. After washing three times with TBST, the membranes were incubated with secondary antibody (1:2000 dilution) overnight at 4°C, then washed again, and finally developed with ECL solutions (Santa Cruz Biotechnology).

Cell surface biotinylation assay. Cells were biotinylated with 500 µg/ml EZ-link sulfo-NHS-Ss-biotin (Pierce) in PBS for 1 h at 4°C. After quenching with PBS containing 100 mM glycine, the cells were lysed in RIPA buffer (25 mM Tris, pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1% Triton X-100, 0.1% SDS, and proteasine inhibitor mixture). Supernatants from cell lysates were incubated with UltraLink Plus immobilized streptavidin beads (Pierce) overnight at 4°C. After being washed with RIPA buffer five times, bound proteins were eluted by boiling for 5 min and analyzed by Western blot with an anti-TRPV1 antibody.

In vitro kinase assay. The in vitro Cdk5 kinase assay was conducted as described previously (Yang et al., 2007). Briefly, rat DRG extracts were immunoprecipitated with an anti-Cdk5 antibody, and the immunoprecipitates were washed four times with TBS containing 0.1% Triton X-100 and twice with assay buffer (20 mM Tris, pH 7.5, 20 mM MgCl₂, 1 mM EDTA, 1 mM EGTA, and 0.1 mM dithiothreitol) then resuspended to a final volume of 25 µl in assay buffer. To initiate the reaction, 10 µl of phosphorylation mix (assay buffer containing 5 µCi of [γ-³²P]ATP and containing 10% FBS), and 2 × 10⁵ DRG neurons were plated onto a 35 mm dish coated with poly-D-lysine (Sigma–Aldrich). After 15 min, medium was replaced with Neurobasal medium supplemented with 2% B27, 2 mM GlutaMAX-I (Invitrogen), and 100 ng/ml mouse NGF (Promega). Five micromolar AraC (Sigma–Aldrich) was added to the culture 18–24 h after plating and maintained until the end of experiments. The cultures were infected with lentiviruses (LVs) on day 3 or treated with the TAT fusion peptides (10 µM) or roscovitine (30 µM) on day 7.
one of the following His6 fusion proteins: His6–motor FHA, His6–motor, His6–FHA, or His6–FHA (Stoelting). The paw-withdrawal threshold was calculated using the up–down method (Chaplan et al., 1994). The basal heat sensitivity and the basal mechanical sensitivity of rats that had recovered from catheter implantation surgery were tested before drug administration. Thirty microliters of TAT–T506 peptide (1 µg/µl) or TAT–T506A peptide (1 µg/µl) was intrathecally administered 30 min before the injection of CFA (100 µl) into the plantar surface of the hindpaw.

**Behavioral assessment.** Heat sensitivity was assessed by measuring the paw-withdrawal latency in response to a radiant heat stimulus applied to the core of the plantar surface of the hindpaw (Hargreaves et al., 1988; Zhu et al., 2008). Mechanical sensitivity was tested by von Frey filaments (Stoelting). The paw-withdrawal threshold was calculated using the up–down method (Chaplan et al., 1994). The basal heat sensitivity and the basal mechanical sensitivity of rats that had recovered from catheter implantation surgery were tested before drug administration.

**Isolation of DRG neurons and calcium imaging.** Isolation of DRG neurons and fura-2 AM-based Ca2+ imaging experiments were performed as described previously (Carlton et al., 2011). Rats were treated with intrathecal delivery of 30 µl of TAT–T506 peptide (1 µg/µl) or TAT–T506A peptide (1 µg/µl) followed by injection of 100 µl of 25% CFA (CFA was diluted with IFA) into the left hindpaw. The heat hyperalgesia and the mechanical alldynia of the rats were assessed 1, 2, 3, and 4 d after CFA injection. For the experiments assessing the effect of TAT–T506 peptide on the basal heat sensitivity, the same dose of TAT peptides were injected intrathecally, and the basal heat sensitivity was tested 1.5 h, 2.5 h, 3.5 h, and 1 d after intrathecal injection.

**Statistical analyses.** Data are expressed as mean ± SEM. Statistical analyses were performed using the Prism 4.0 software. Differences between groups were compared using either the Student’s t test or one-way ANOVA, followed by Newman–Keuls post hoc tests or two-way repeated-measures ANOVA, followed by Bonferroni’s post hoc tests. Statistical significance was set at p < 0.05. For Western blot, the immunoreactive bands were scanned and analyzed quantitatively by densitometry with the TotalLab software.

**Results**

Cdk5 activity regulates TRPV1 membrane localization

The function of TRPV1 is modulated by its gating properties and the total amount of receptor at the cell surface. It has been reported that Cdk5 can modulate capsaicin-induced calcium influx (Pareek et al., 2007). Here, we addressed whether Cdk5 can regulate the level of TRPV1 surface expression. Because Cdk5 displays constitutive kinase activity in the basal state, we first inhibited endogenous Cdk5 activity with roscovitine, a specific inhibitor of Cdk5, to investigate the issue. Cells of the following three types were treated with 30 µM roscovitine for 5 h: CHO cells stably expressing TRPV1 (TRPV1–CHO), TRPV1 transiently transfected DRG-derived F11 cells (mouse N18TG2 neuroblastoma × rat DRG, hybridoma), and primary cultured DRG neurons. Surface biotinylation assays revealed that treatment with roscovitine substantially decreased the surface TRPV1 levels in all three cell models (Fig. 1A–C). The ratio of surface to total TRPV1 was reduced to 58.7 ± 5.9% (p = 0.006, n = 4) of the control in roscovitine-treated TRPV1–CHO cells (Fig. 1A) and to 40.7 ± 1.9% (p = 0.001, n = 3) of the control in roscovitine-treated F11 cells (Fig. 1B) and to 51 ± 4.6% (p = 0.0087, n = 3) of the control in roscovitine-treated DRG neurons (Fig. 1C). In contrast, the number of surface NR1 subunits of the NMDA receptor in F11 cells was not reduced after the addition of roscovitine (Fig. 1D), indicating that roscovitine specifically reduces TRPV1 membrane localization. The total amount of TRPV1 was not significantly altered (Fig. 1A–C). These data show that the basal activity of Cdk5 is required for the surface localization of TRPV1s in basal conditions.

In an additional study, we transfected TRPV1–CHO cells with Cdk5, its activator p35, or a dominant-negative form of Cdk5 (D144N–Cdk5) and measured the surface TRPV1 levels. Overexpression of Cdk5 (Fig. 1E) or p35 (Fig. 1F), which elevates intracellular Cdk5 activity, significantly increased the ratio of surface to total TRPV1 by ~35.9% (p < 0.01, vector vs Cdk5) or ~50.4% (p < 0.001, GFP vs GFP–p35): this effect was not blocked but reversed by exposure to roscovitine (30 µM, 5 h) (Fig. 1E; ~28.2% reduction, vector vs Cdk5+Ros, p < 0.01; Fig. 1F; ~34.4% reduction, GFP vs GFP–p35+Ros, p < 0.01). Furthermore, overexpression of D144N–Cdk5, which competitively inhibits endogenous Cdk5 activity, resulted in an effect similar to roscovitine treatment (Fig. 1E); the ratio of surface to total TRPV1 was reduced by ~33.4% in cells expressing D144N–Cdk5, p < 0.01). TRPV1 total protein levels were comparable among the groups. Together, these results suggest that Cdk5 positively regulates membrane localization of TRPV1s, and the number of surface TRPV1s is directly proportional to Cdk5 activity.

Cdk5 activation increases TRPV1 anterograde transport after inflammation

Previous studies have shown that TRPV1s are normally transported from the DRG to peripheral terminals along the sciatic nerve (Guo et al., 1999), that TRPV1 production is increased after inflammation, and that inflammation-induced TRPV1s are also anterogradely transported to the periphery (Li et al., 2002). Consistently, our data showed that the TRPV1 protein levels in the DRG somas, the peripheral processes, and the sciatic nerves are significantly increased 1 d after CFA-induced inflammation (Fig. 2A; 24.6% increase in the somas, p = 0.044; 53.9% increase in the peripheral processes, p = 0.0215; 40.5% increase in the sciatic nerves, p = 0.0481; n = 4), demonstrating that inflammation induces an increase in TRPV1 protein levels and TRPV1 antero-
Figure 1. Cdk5 plays a regulatory role in TRPV1 membrane localization. A–C, Roscovitine reduces the surface TRPV1 levels in TRPV1–CHO cells (A), F11 cells transfected with GFP–TRPV1 (B), and primary cultured DRG neurons (C). Cells were treated with 30 μM roscovitine for 5 h. The surface biotinylation assay was used to detect the amount of TRPV1 at the cell surface. The quantitative analyses show the ratio of surface to total TRPV1 normalized to the DMSO control and the total TRPV1 protein levels normalized to the DMSO control. Data were analyzed by two-tailed paired t test. **p < 0.01, ***p < 0.001 compared with DMSO control group, n = 3–4. Error bars indicate SEM. Ros, Roscovitine. D, The levels of surface NR1 subunits of the NMDA receptor in F11 cells are not reduced by roscovitine treatment (30 μM, 5 h). E, Overexpression of Cdk5 increases and overexpression of D144N–Cdk5 decreases the levels of surface TRPV1 in TRPV1–CHO cells. Cells were transfected with pcDNA3.1–vector, pcDNA3.1–Cdk5, or pcDNA3.1–D144N–Cdk5. For the Cdk5+ Ros group, cells expressing Cdk5 were treated with roscovitine (30 μM) for 5 h. Quantitative analysis show the ratio of surface to total TRPV1 normalized to the vector control (top) and the total TRPV1 protein levels normalized to the vector control (bottom). Data were analyzed by one-way ANOVA, followed by Newman–Keuls post hoc tests. **p < 0.01 compared with the vector group; ###p < 0.001 compared with the Cdk5 group, n = 5–6. Error bars indicate SEM. F, Overexpression of p35 increases the levels of surface TRPV1 in TRPV1–CHO cells. Cells were transfected with pEGFP–C2–p35 or pEGFP–C2–vector. For the GFP–p35 + Ros group, cells expressing GFP–p35 were treated with 30 μM roscovitine for 5 h. Quantitative analysis of the ratio of surface to total TRPV1 normalized to the GFP control (top) and the total TRPV1 protein levels normalized to the GFP control (bottom) are shown. Data were analyzed by one-way ANOVA, followed by Newman–Keuls post hoc tests. **p < 0.01, ***p < 0.001 compared with the GFP group; ###p < 0.001 compared with the GFP–p35 group, n = 4–5. Error bars indicate SEM.
Cdk5 is a small proline-directed serine/threonine kinase and is implicated in the regulation of cellular processes by phosphorylating certain substrates (Dhavan and Tsai, 2001). In addition to an absolute requirement for proline in the +1 position, Cdk5 shows a marked preference for a basic residue in the +3 position and phosphorylates the consensus sequence (S/T)PX(K/H/R), where X is any amino acid (Beaudette et al., 1993; Songyang et al., 1996).

It is known that N-kinesins, which generally drive microtubule plus-end-directed cargo moving, are a critical determinant of anterograde transport toward the cell periphery or axon terminals in neurons (Hirokawa et al., 2009). Through sequence analysis, we found a “TPQK” sequence, which is consistent with the consensus phosphorylation sequence of Cdk5 (T/SPXK/H/R), in the FHA domain of KIF13B (Fig. 3A, B). This sequence is conserved across humans, rats, and mice (Fig. 5B), and the FHA domain of KIF13B has been reported to be a cargo binding domain (Horiguchi et al., 2006). Thus, we speculated that KIF13B might mediate the Cdk5-regulated anterograde transport of TRPV1s.

To determine whether KIF13B drives the anterograde transport of TRPV1s, we first tested whether KIF13B can associate with TRPV1. Co-IP studies using TRPV1–CHO cells expressing GFP–motor FHA and in F11 cells coexpressing GFP–motor FHA and GFP–TRPV1 revealed binding between TRPV1 and the KIF13B–motor FHA domain (Fig. 3C). TRPV1 immunoprecipitated from lysates of TRPV1–CHO cells also pulled down exogenously expressed His6–motor FHA (Fig. 3D). More significantly, the FHA domain seems to be the actual binding domain for TRPV1 (seen also Fig. 5D); this is also suggested indirectly by the lack of interaction between TRPV1 and the KIF13B–motor domain (Fig. 5E, left).

Next, we used RNAi to knock down KIF13B expression and measured the effect on TRPV1 transport. KIF13B shRNAs efficiently knocked down endogenous KIF13B expression in cultured DRG neurons (Fig. 3E; 44.5 ± 4.8% of the control, p = 0.0074, n = 3). Biotinylation assays revealed that knockdown of KIF13B in DRG neurons resulted in a significant decrease in the number of surface TRPV1s (Fig. 3F; 74.4 ± 5.7% of the control, p = 0.0457, n = 3); this indicates that KIF13B is required for TRPV1 membrane trafficking. To further confirm that TRPV1 membrane trafficking is KIF13B dependent, we transfected GFP–motor FHA or GFP–FHA into TRPV1–CHO cells. Biotinylation assays showed that both treatments induced notable decreases in the content of surface TRPV1s compared with the transfection of GFP alone (Fig. 3G; the ratio of surface to total TRPV1 was reduced by ~25.9% in cells expressing GFP–motor FHA, p < 0.01, and ~38.1% in cells expressing GFP–FHA, p < 0.001, n = 3), indicating that both truncations disrupt the motor–cargo interaction. Together, the above results reveal that KIF13B mediates TRPV1 membrane trafficking, and the FHA domain of KIF13B functions as a TRPV1 binding domain.

**Figure 2.** Cdk5 activation induced by inflammation increases TRPV1 anterograde transport to the periphery. **A.** Western blot analysis showing alterations in the TRPV1 protein levels in the indicated tissues 1 d after CFA-induced inflammation. The quantitative analysis in the right shows the comparative levels of TRPV1 over the naive control after normalizing to β-actin. *p < 0.05, n = 4, two-tailed paired t test within each group. Error bars indicate SEM. Note that the p35 protein levels are primarily increased after inflammation, indicating the activation of Cdk5. **B.** Immunoprecipitation of TRPV1s from lysates of indicated tissues showing the effect of intrathecal delivery of roscovitine (Ros) on the amount of TRPV1 in these tissues. Either roscovitine (100 μg) or DMSO was delivered intrathecally to rats 30 min before the injection of CFA into a hindpaw. The quantitative analysis in the right shows the comparative levels of TRPV1 over the naive control after normalizing to β-actin. *p < 0.01, n = 7, two-tailed paired t test within each group. Error bars indicate SEM.
Figure 3. KIF13B transports TRPV1 to the cell surface. A, Schematic diagram of the domain structure of KIF13B/GAKIN and the constructs used in the present study. B, Comparison of the rat, mouse, and human KIF13B sequences containing the putative phosphorylation site of Cdk5. Threonine-506 is conserved across the species shown here. * indicates identical residues. C, Co-IP of TRPV1 and GFP–motor FHA. TRPV1–CHO cells (left) were transfected with pEGFP–C2–motor FHA or pEGFP–C2–vector, and F11 cells (right) were cotransfected with GFP–TRPV1 and pEGFP–C2–motor FHA or pEGFP–C2–vector. TRPV1s were immunoprecipitated with an anti-TRPV1 antibody, and the immunoblots were probed with an anti-GFP antibody. Lysates of cells expressing GFP were used as controls. Inputs represent the direct immunoblotting of the lysates. D, In vitro pull-down assay. TRPV1s were immunoprecipitated from cell lysates containing His6–motor FHA, which was expressed in bacteria. The immunoblots were detected with an anti-His antibody. E, Western blot analysis demonstrating an efficient decrease in KIF13B protein levels in primary cultured DRG neurons after infection with LVs expressing KIF13B shRNAs. **p < 0.01, n = 3, two-tailed paired t test. Error bar indicates SEM. F, Effect of KIF13B knockdown on the surface targeting of TRPV1s in primary cultured DRG neurons. The amount of membrane localized TRPV1 was detected with a surface biotinylation assay. Detection of N-cadherin was used as a control for the equal loading of biotinylated protein. The quantitative analysis shows the ratio of surface to total TRPV1 normalized to the control. *p < 0.05, n = 3, two-tailed paired t test. Error bar indicates SEM. G, Effect of overexpression of GFP–motor FHA or GFP–FHA on the surface targeting of TRPV1s in TRPV1–CHO cells. The top shows the quantitative analysis of the ratio of surface to total TRPV1 normalized to the GFP control. The bottom shows the total TRPV1 protein levels normalized to the GFP control. **p < 0.01, ***p < 0.001 compared with the GFP control, n = 3, one-way ANOVA, followed by Newman–Keuls post hoc tests. Error bars indicate SEM. Experiments in C and D were repeated at least three times.
Cdk5 binds to and phosphorylates KIF13B

As mentioned above, KIF13B possesses a conserved phosphorylation sequence for Cdk5 in the FHA domain (Fig. 3B); however, it remains to be clarified whether Cdk5 can phosphorylate KIF13B. To address this question, we first examined whether Cdk5 binds to KIF13B. GFP–motor FHA was coexpressed with Cdk5 or p35 in TRPV1–CHO cells, and Co-IP assays revealed that both Cdk5 and p35 were able to precipitate GFP–motor FHA (Fig. 4A). Then, an in vitro kinase assay was performed, and the results showed that Cdk5 phosphorylated the KIF13B–motor domain (Fig. 4B, left). Based on the consensus phosphorylation sequence of Cdk5 (T/SPXK/H/R), we hypothesized that the Thr-506 residue located in the TPQK sequence was phosphorylated by Cdk5. To test this hypothesis, we performed an in vitro kinase assay using rat DRG lysates and incubated with recombinant His6 fusion proteins in the presence of radioactive [32P]ATP. The results showed that Cdk5 phosphorylated the KIF13B–motor FHA and KIF13B–FHA domains in vitro but did not phosphorylate the KIF13B–motor domain (Fig. 4B, right). These results suggest that Cdk5 phosphorylates KIF13B in vivo.

Figure 4. Phosphorylation of KIF13B by Cdk5. A, Co-IP of GFP–motor FHA and Cdk5 (left) or GFP–p35 (right). Lysates of TRPV1–CHO cells coexpressing pEGFP–C2–motor FHA and pcDNA3.1(+)–Cdk5 (left) or pEGFP–C2–p35 (right) were immunoprecipitated with an anti-Cdk5 or an anti-p35 antibody, respectively. Lysates of cells coexpressing pEGFP–C2–vector and pcDNA3.1(+)–Cdk5 (left) or pEGFP–C2–p35 (right) were used as controls. Immunoblots were probed with an anti-GFP antibody. Inputs represent the direct immunoblotting of the lysates. B, In vitro kinase assay. Cdk5 was immunoprecipitated from rat DRG lysates and incubated with the indicated His6 fusion proteins in the presence of radioactive [32P]ATP. Left side of each panel, Autoradiogram of phosphorylated proteins (arrowheads indicate the nonspecific bands). Right side of each panel, The amount of recombinant His6 fusion protein (indicated by an asterisk) shown by Coomassie blue staining. C, Threonine phosphorylation of GFP–motor FHA in cells treated with roscovitine (30 μM) or DMSO for 5 h. Lysates of TRPV1–CHO cells expressing pEGFP–C2–motor FHA or F11 cells expressing pEGFP–C2–motor FHA were immunoprecipitated with a phosphothreonine-specific antibody, and the immunoblots were probed with a GFP antibody. Inputs represent the direct immunoblotting of the lysates. D, Threonine phosphorylation of GFP–motor FHA in cells expressing empty vector, Cdk5, or D144N–Cdk5. TRPV1–CHO cells were cotransfected with pEGFP–C2–motor FHA and pcDNA3.1(+)–vector, pcDNA3.1(+)–Cdk5, or pcDNA3.1(+)–D144N–Cdk5. Treatment of cells and detection of immunoblots were the same as in C. E, Threonine phosphorylation of GFP–motor FHA is reduced by T506A mutation. TRPV1–CHO cells and F11 cells were transfected with pEGFP–C2–motor FHA or pEGFP–C2–motor FHA T506A. Treatment of cells and detection of immunoblots were the same as in C. All above experiments were repeated at least three times.
Figure 5. The binding between TRPV1 and KIF13B is regulated by Cdk5 activity and requires Thr-506 phosphorylation. A, Roscovitine inhibits the Co-IP of TRPV1 and GFP–motor FHA. TRPV1–CHO cells (left) transfected with pEGFP–C2–motor FHA and F11 cells (right) cotransfected with GFP–TRPV1 and pEGFP–C2–motor FHA were treated with roscovitine (30 μM) or DMSO for 5 h. Cell lysates were immunoprecipitated with a TRPV1 antibody, and the immunoblots were detected with a GFP antibody. Inputs represent the direct immunoblotting of the lysates. B, Overexpression of Cdk5 promotes and overexpression of D144N–Cdk5 inhibits the Co-IP of TRPV1 and GFP–motor FHA. TRPV1–CHO cells were cotransfected with pEGFP–C2–motor FHA and pcDNA3.1(+)-vector, pcDNA3.1(+)-Cdk5, or pcDNA3.1(+)-D144N–Cdk5, and immunoprecipitation and immunoblot were performed as described in A. C, Overexpression of p35 promotes the Co-IP. TRPV1–CHO cells were cotransfected with pEGFP–C2–motor FHA and pEGFP–C2–p35 or pEGFP–C2–vector, and immunoprecipitation and immunoblot were performed as described in A. D, In vitro pull-down assay. TRPV1s were immunoprecipitated from cell lysates containing His6–FHA or His6–FHA T506A expressed in bacteria, and the immunoblots were detected with a His antibody. Input shows the equal addition of His6 fusion proteins. E, Co-IP assays showing that Thr-506 phosphorylation contributes to the association between TRPV1 and GFP–motor FHA. TRPV1–CHO cells were transfected with the indicated plasmids (left), and F11 cells were cotransfected with GFP–TRPV1 and the indicated plasmids (right). Anti-TRPV1 immunoprecipitates were analyzed by immunoblot with a GFP antibody; inputs represent the direct immunoblotting of the lysates. Note that TRPV1 binds to GFP–motor FHA but not GFP–motor. All above experiments were repeated at least three times.
decreased by roscovitine treatment (30 μM). In the control peptide (bottom), Thr-506 was substituted with alanine. B. Effects of TAT peptides on the levels of surface TRPV1 in primary cultured DRG neurons. Neurons were treated with 10 μM TAT–T506 peptide or TAT–T506A peptide for 3 h and subjected to a surface biotinylation assay. Detection of N-cadherin was used as a control for the equal loading of biotinylated protein. The quantitative analysis in the right shows the comparative levels of surface TRPV1 over the TAT–T506A control after normalizing to surface N-cadherin levels; **p < 0.01, n = 4, two-tailed paired r-test. Error bar indicates SEM.

Figure 6. Construction of TAT–T506 fusion peptide and its negative effect on TRPV1 membrane trafficking. A, Schematic diagram of the TAT–T506 and control TAT–T506A peptides. Top, The letters on the dark background indicate the 15 aa sequence of the FHA domain of rat KIF13B, which contains Thr-506 (white letter). Nine amino acid residues (letters on the light background) of the HIV TAT protein were fused to this sequence. In the control peptide (bottom), Thr-506 was substituted with alanine. B, Effects of TAT peptides on the levels of surface TRPV1 in primary cultured DRG neurons. Neurons were treated with 10 μM TAT–T506 peptide or TAT–T506A peptide for 3 h and subjected to a surface biotinylation assay. Detection of N-cadherin was used as a control for the equal loading of biotinylated protein. The quantitative analysis in the right shows the comparative levels of surface TRPV1 over the TAT–T506A control after normalizing to surface N-cadherin levels; **p < 0.01, n = 4, two-tailed paired r-test. Error bar indicates SEM.

Cdk5 may regulate the motor–cargo interaction. To test this hypothesis, TRPV1–CHO cells transfected with GFP–motor FHA and F11 cells cotransfected with GFP–TRPV1 and GFP–motor FHA were treated with roscovitine (30 μM, 5 h). Co-IP experiments revealed that roscovitine significantly decreased the number of TRPV1–KIF13B–motor FHA complexes (Fig. 5A). Conversely, overexpression of Cdk5 (Fig. 5B) or its activator p35 (Fig. 5C) in TRPV1–CHO cells remarkably increased the number of complexes. Overexpression of D144N–Cdk5, however, decreased the number of complexes (Fig. 5B). These results indicate that Cdk5 kinase activity is both necessary and sufficient for KIF13B–TRPV1 interaction and suggest that Cdk5 regulates TRPV1 membrane trafficking by mediating the KIF13B–TRPV1 association.

In the following studies, we examined the effect of Thr-506 phosphorylation of KIF13B on its association with TRPV1. TRPV1 immunoprecipitated from lysates of TRPV1–CHO cells pulled down exogenously expressed His₆–FHA but not the T506A mutant (Fig. 5D). Co-IP studies in both TRPV1–CHO cells (Fig. 5E, left) and F11 cells (Fig. 5E, right) showed that binding between TRPV1 and the KIF13B–motor FHA was significantly inhibited by the T506A mutation. The phosphorylation-mimicking mutation T506D retained the ability to interact with TRPV1 but did not increase the interaction of KIF13B–motor FHA with TRPV1 over that of wild-type KIF13B–motor FHA (Fig. 5E, left). These data indicate that phosphorylation at Thr-506 is required for KIF13B–TRPV1 association. Thus, Cdk5 mediates KIF13B–TRPV1 association, at least partially, by phosphorylating Thr-506.

Phosphorylation at Thr-506 is necessary for TRPV1 membrane trafficking

To further investigate the role of Thr-506 phosphorylation in KIF13B-dependent TRPV1 membrane trafficking, we constructed a peptide with 15 aa of the KIF13B–FHA domain, which included the TPQK sequence, and the peptide was rendered cell permeable by fusion with the HIV TAT protein sequence (RKKRRQRRR) (termed TAT–T506). As a control peptide, Thr-506 was replaced with alanine (termed TAT–T506A) (Fig. 5B). The TAT–T506 peptide targeting Thr-506 of KIF13B was used as a dominant-negative approach to study the consequences of disrupting endogenous Thr-506 phosphorylation. Primary cultured DRG neurons were treated with 10 μM TAT fusion peptide for 3 h. Subsequently, biotinylation assays showed that the TAT–T506 peptide significantly decreased the amount of surface TRPV1 (Fig. 6E; 78.7 ± 3.4% of the control, p = 0.0081, n = 4). Thus, Thr-506 phosphorylation is indeed a critical determinant in KIF13B-mediated trafficking of TRPV1 to the cell surface.

Disruption of Thr-506 phosphorylation attenuates functional TRPV1 membrane targeting and the development of heat hyperalgesia after inflammation

Because Thr-506 phosphorylation is necessary for Cdk5-mediated regulation of TRPV1 (Figs. 5, 6), it might also
be crucial for Cdk5-activation-induced modulation of TRPV1 channel function and heat hyperalgesia that develops after inflammation.

We first used calcium imaging to test the functional consequences of inhibiting Thr-506 phosphorylation after inflammation. The TAT–T506 peptide (30 μg) or the control peptide (30 μg) was injected intrathecally 30 min before the injection of CFA into a hindpaw. The uptake of TAT peptides into DRGs has been observed previously, and the peak concentration appears ~3 h after delivery (Xie et al., 2009). Two hours after inflammation, ipsilateral L4 and L5 DRG neurons were acutely dissociated and subjected to fura-2 calcium imaging. Capsaicin (1 μM) evoked a rapid robust increase in intracellular Ca\(^{2+}\) concentration in neurons pretreated with the control peptide, whereas neurons pretreated with the TAT–T506 peptide showed delayed calcium signals and the intracellular Ca\(^{2+}\) concentration of these neurons increased apparently slower than that of the control neurons (Fig. 7A), although the maximum calcium signals are similar in the two groups. Measurements of the area under the curve within 2 min after the beginning of the stimulation revealed weaker capacities of the TAT–T506 peptide-pretreated neurons for the accumulation of intracellular Ca\(^{2+}\) (Fig. 7B; 43.8 ± 1.3 vs 52.3 ± 2.0 for TAT–T506, n = 104 vs TAT–T506A, n = 55, from three independent experiments, p = 0.0003), suggesting an obvious inhibition of TRPV1 channel function by the TAT–T506 peptide.

We further determined the effects of disruption of Thr-506 phosphorylation on heat sensitivity after inflammation. We assessed heat-evoked behavioral responses after CFA injections preceded by intrathecal TAT–T506 peptide (30 μg) or TAT–T506A peptide (30 μg) delivery. Rats pretreated with the TAT–T506A peptide exhibited a significant decrease in radiant heat-evoked paw-withdrawal latency after inflammation, whereas inflammation-induced thermal hyperalgesia was relatively attenuated in rats pretreated with the TAT–T506 peptide at 1 h, p < 0.01; 8.0 ± 0.7 vs 5.0 ± 0.4 s for TAT–T506 vs TAT–T506A at 1 h, p < 0.001; n = 19–20). The inhibition effect of the TAT–T506 peptide became weaker 6 h after inflammation and disappeared 1 d after inflammation (Fig. 7D). The basal heat-evoked paw-withdrawal latency of the rats treated with the TAT–T506 peptide at 1 h and 2 h after the induction of inflammation (Fig. 7D; 7.6 ± 0.6 vs 4.9 ± 0.5 s for TAT–T506 vs TAT–T506A at 1 h, p < 0.01; 8.0 ± 0.7 vs 5.0 ± 0.4 s for TAT–T506 vs TAT–T506A at 2 h, p < 0.001; n = 19–20). The inhibition effect of the TAT–T506 peptide became weaker 6 h after inflammation and disappeared 1 d after inflammation (Fig. 7D). The basal heat-evoked paw-withdrawal latency of the rats treated with the TAT–T506 peptide is not significantly different from that of the control peptide-treated rats (Fig. 7C), and there is no significant difference in the withdrawal threshold to mechanical stimuli (von Frey hair) after inflammation between the two groups (Fig. 7E). These results suggest that disruption of Thr-506 phosphorylation with the TAT–T506 peptide during inflammation can alleviate heat hyperalgesia but not mechanical allodynia that develops after inflammation, and this treatment does not affect the basal heat sensitivity.

**Discussion**

We have investigated the regulatory mechanisms of fast anterograde transport of TRPV1s in DRG neurons. We demonstrate that Cdk5 positively regulates TRPV1 membrane trafficking by mediating KIF13B–TRPV1 association. Furthermore, we find that Cdk5-dependent phosphorylation of KIF13B at Thr-506 is necessary for Cdk5-mediated motor–cargo association and contributes to efficient TRPV1 transport (Fig. 8A).

Previous studies showed that Cdk5 activity regulates thermal pain sensation (Pareek et al., 2006, 2007). Mice overexpressing p35, which exhibit elevated Cdk5 activity, show increased sensitivity to noxious heat (hyperalgesia). In contrast, p35 knock-out mice or nociceptor-specific Cdk5 conditional knock-out mice, which exhibit reduced Cdk5 activity, show impaired thermal nociception (hyperalgesia). Consistent with these results, we reveal that Cdk5 activity regulates the density of functional TRPV1s at the neuronal surface (Fig. 1), and this in turn affects the heat sensitivity of nociceptors. This finding provides insight into Cdk5 activity-dependent regulation of pain signaling and suggests that the basal activity of Cdk5 is important for the normal function of TRPV1.

In searching for the motor protein responsible for Cdk5-regulated TRPV1 membrane trafficking, we speculated that this motor should be modulated by Cdk5. Fortunately, we found a
consensus phosphorylation sequence of Cdk5 in the FHA domain (a cargo binding domain) of KIF13B motor protein. The involvement of KIF13B in TRPV1 trafficking was confirmed by co-IP with an anti-TRPV1 antibody, RNAi, and a dominant-negative approach in which the TRPV1 binding domain was overexpressed (Fig. 3C,F,G). However, we cannot rule out the possibility that other kinesins also contribute to Cdk5-regulated TRPV1 anterograde transport.

A feature that distinguishes kinesin-3 family from other kinesin families is that all members of this group contain an FHA domain. The FHA domain is present in a wide variety of proteins from both prokaryotes and eukaryotes and acts as a protein interaction domain (Hammet et al., 2003; Mahajan et al., 2008). Here, we find that the FHA domain of KIF13B serves as a binding domain of TRPV1-containing vesicles (Fig. 5D,E).

We did not, however, investigate whether it is the only binding domain for TRPV1 or whether other domains, including the MAGUK binding stalk (MBS) domain, the C-terminal tail, and the stalk region between them, may also interact with TRPV1. The MBS domain is a binding domain for human Discs large (Dlg) tumor suppressor and might be involved in KIF13B/Dlg-mediated transport of some cargos (Yamada et al., 2007; Bolis et al., 2009). A recent study showed that multiple domains of KIF13B are involved in its association with CARD11, a critical scaffold protein in T-cell receptor signaling (Lamason et al., 2010). Thus, we cannot exclude the possibility that a TRPV1-containing vesicle may interact with other domains of KIF13B at the same time. Despite this, the interaction between TRPV1-containing vesicle and the FHA domain is definitely essential for TRPV1 transport because disruption of their interaction via the overexpression of exogenous KIF13B–motor FHA or KIF13B–FHA domain impaired TRPV1 membrane trafficking (Fig. 3G).

Kinesins usually bind to cargo vesicles via adaptor proteins or scaffold proteins that determine the specificity of cargos transported by each motor (Hirokawa et al., 2009). In another study, KIF13B was found to transport phosphatidylinositol-3,4,5-triphosphate (PIP3)-containing vesicles to neurite endings via the adaptor protein centaurin α1/PIP3 binding protein (Horiguchi et al., 2006; Tong et al., 2010), and the FHA domain is just the domain that directly interacts with centaurin α1, which, in turn, specifically binds to PIP3. In the case of TRPV1, the motor associates with the cargo in a phosphorylation-dependent manner; however, it is not known whether the FHA

Figure 8. Schematic model representing Cdk5-mediated motor–cargo association (A) and Cdk5 activity-regulated TRPV1 membrane trafficking (B, C). A. Cdk5-mediated phosphorylation of KIF13B at Thr-506 is necessary for the KIF13B–TRPV1 association. Other Cdk5-dependent phospho-regulated mechanisms may also be required. Whether KIF13B binds to a TRPV1-carrying vesicle via adaptor proteins is unknown. B. Under normal conditions, basal Cdk5 activity in nociceptive neurons is low, and only a few TRPV1-carrying vesicles are loaded and transported by phosphorylated KIF13B from the Golgi apparatus to the neuronal surface, maintaining a low surface level for normal sensitivity to noxious heat. C. After peripheral inflammation, Cdk5 activity is greatly elevated, and more TRPV1-carrying vesicles are loaded onto the motor and delivered to the cell surface. As a result, the number of TRPV1s at the neuronal surface (the plasma membrane of the soma and the peripheral axon) increases, contributing to the development and possibly the maintenance of heat hyperalgesia. If, at this time, the activated Cdk5-induced phosphorylation of KIF13B is disrupted by TAT–T506 peptide, the increase in TRPV1 membrane trafficking is prevented and the heat hyperalgesia is relieved to some extent.
domain interacts with TRPV1 directly or indirectly because all binding assays were performed in the presence of other cellular proteins. Both patterns may be possible. TRPV1 has large N- and C-terminal cytosolic domains, both of which are outside of the vesicle and are used to interact with intracellular proteins. The N-terminal region contains six ankyrin repeats that often mediate protein–protein interactions (Lishko et al., 2007), whereas the C terminus can interact with scaffold protein AKAP79/150 (A-kinase anchoring protein 79/150) (Zhang et al., 2008). Therefore, additional studies are required to clarify the molecular details of the association between KIF13B and TRPV1-containing vesicles and how phosphorylation of KIF13B promotes the formation of the complex.

Kinesin phosphorylation appears to regulate the motor–cargo interaction. GSK3 (glycogen synthase kinase 3) phosphorylates kinesin light chains and leads to the removal of kinesin from vesicles (Morfini et al., 2002, 2004). CaMKII-dependent phosphorylation of KIF17 at Ser-1029 disrupts the KIF17–Mint1 association and results in the release of transported cargo from the phosphorylated molecular motor (Guillaud et al., 2008). JNK pathway kinase-mediated phosphorylation inhibits the interaction between kinesin light chains and the JIP1 (JNK interacting protein 1) adaptor (Horiuchi et al., 2007). Altogether, phosphorylation of kinesin acts as a molecular switch for motor–cargo dissociation. However, our results show that phosphorylation of KIF13B by Cdk5 contributes to motor–cargo association. This is the first demonstration of a positive role of kinesin phosphorylation in controlling motor–cargo interaction and provides insight into the dynamic control of intracellular transport in vivo. We find that phosphorylation at Thr-506 is necessary for KIF13B–TRPV1 association because mutation of Thr-506 to a nonphosphorylatable alanine specifically inhibited the interaction (Fig. 5D,E). However, and contrary to our expectations, mutation to aspartic acid, which mimics a phosphate moiety, did not result in increased affinity to TRPV1 compared with wild-type KIF13B–motor FHA (Fig. 5E). One interpretation is that this mutation does not mimic phosphorylation, and perhaps a glutamic acid substitution would be better. Another interpretation is that Thr-506 phosphorylation is not sufficient for KIF13B–TRPV1 association, which suggests that other Cdk5-dependent regulatory mechanisms may coexist. Thus, we conclude that phosphorylation at Thr-506 is necessary, but not necessarily sufficient, for Cdk5-mediated KIF13B–TRPV1 association. More specifically, Cdk5 mediates the motor–cargo association, at least partially, by phosphorylating Thr-506.

Because TRPV1 plays a central role in mediating inflammatory heat hyperalgesia, a key issue to be addressed is whether proinflammatory mediators can sensitize TRPV1 by activating Cdk5-regulated TRPV1 peripheral transport. Our previous study demonstrated that peripheral inflammation (produced by CFA injection) induces the activation of Cdk5 in DRGs (Yang et al., 2007). Here, we find that preventing the elevation of Cdk5 activity by intrathecal delivery of roscovitine efficiently decreased TRPV1 anterograde transport (Fig. 2B). Thus, we conclude that Cdk5 activation can increase peripheral transport of TRPV1s. Consistent with this conclusion, Cdk5 activation contributes to inflammatory heat hyperalgesia (Yang et al., 2007). Moreover, inhibition of increased TRPV1 trafficking through preventing the Cdk5-dependent phosphorylation at Thr-506 alleviated inflammatory heat hyperalgesia (Fig. 7). Therefore, we propose a model in which Cdk5 activity regulates the magnitude of TRPV1 anterograde transport (Fig. 8B,C). When activated by peripheral inflammation, Cdk5 increases the number of KIF13B–TRPV1 complexes, in turn increasing the anterograde transport of TRPV1s, resulting in increased density of TRPV1 at the surface of nociceptive neurons and increased heat sensitivity (Fig. 8C).

Although our study only demonstrates the role of activation of Cdk5-regulated TRPV1 membrane trafficking in the development phase of heat hyperalgesia (within 24 h after CFA injection) (Fig. 7D), activation of Cdk5-regulated TRPV1 trafficking may also contribute to the maintenance phase of heat hyperalgesia because activation of Cdk5 by CFA injection is sustained for at least 1 week (Yang et al., 2007).

Our results further suggest that Thr-506 of KIF13B might be a potential target for analgesic treatments (Fig. 8C). The TAT–T506 peptide, which could competitively disrupt the phosphorylation of endogenous KIF13B at Thr-506, had an analgesic effect on inflammatory pain and did not affect the basal heat sensitivity (Fig. 7C,D), indicating that the TAT–T506 peptide could be a promising approach for pain management.

In conclusion, this study establishes a Cdk5 activity-regulated TRPV1 membrane trafficking model in which peripheral inflammation-induced activation of Cdk5 and the subsequent upregulation of TRPV1 membrane trafficking play pivotal roles in the development and possibly in the maintenance of heat hyperalgesia. Moreover, phosphorylation of KIF13B at Thr-506 is quite important for Cdk5 regulation of TRPV1 membrane trafficking, and moderate inhibition of Thr-506 phosphorylation during inflammation will be a promising strategy for the treatment of inflammatory thermal pain.

References


